The DOI matches its Crossref record; the references it cites are not checked yet.
Structure–Activity Analysis of Cyclic Multicomponent Lipopeptide Self-Adjuvanting Vaccine Candidates Presenting Group A Streptococcus Antigens
Abstract
(GAS) infection causes a range of life-threatening diseases, including rheumatic heart disease. Cyclic peptides offer an attractive solution for presentation of short peptide antigens due to their stability and structurally constrained conformation. We investigated a cyclic carrier decapeptide incorporating a B cell GAS peptide epitope, a universal T helper epitope, and a synthetic toll-like receptor 2-targeting moiety as a possible self-adjuvanting GAS vaccine. A structure-activity relationship of the cyclic lipopeptide vaccine showed successful induction of J8-specific systemic immunoglobulin G (IgG) antibodies when administered subcutaneously without an additional adjuvant. Interestingly, the physical mixture control induced the highest titers of all vaccine compounds, with antibodies from mice immunized with this physical mixture control shown to effectively opsonize multiple strains of clinically isolated GAS bacteria. This study showed the capability for a self-adjuvanting cyclic delivery system to act as a vehicle for the delivery of GAS peptide antigens to treat GAS infections.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
The citation lists haven’t been fetched yet
References 38 · Cited by 19
Research works printed but not linked: 38
- 10.1086/521263 · DOI
- 10.1056/NEJMoa1603693 · DOI
- 10.5694/mja16.00400 · DOI
- 10.1093/cid/ciy1143 · DOI
- Kaplan M. H., 1963, J. Immunol., 90, 595, 10.4049/jimmunol.90.4.595 · DOI
- 10.1001/jama.1969.03150190037007 · DOI
- 10.3390/vaccines7030058 · DOI
- 10.1039/C5SC03892H · DOI · Paper page
- 10.3389/fimmu.2013.00318 · DOI · Paper page
- 10.1016/j.bmc.2016.03.063 · DOI
- 10.1371/journal.pone.0198658 · DOI
- 10.1093/infdis/jis107 · DOI
- 10.1039/C2CS35413F · DOI
- 10.1002/cmdc.200700315 · DOI
- 10.1016/0040-4039(94)02481-P · DOI
- 10.1039/C7BM00072C · DOI
- 10.1016/0022-1759(92)90033-P · DOI
- 10.1021/acs.biomac.5b00572 · DOI
- Galanos C., 1975, Z. Immunitatsforsch. Exp. Klin. Immunol., 149, 214
- 10.3390/genes9110557 · DOI
- 10.1016/j.peptides.2012.08.021 · DOI
- 10.1016/j.vaccine.2013.04.028 · DOI
- 10.1002/psc.3021 · DOI
- Ahmad Fuaad A. A. H., 2016, Vaccine Design: Methods and Protocols: Volume 1: Vaccines for Human Diseases, 1403, 639, 10.1007/978-1-4939-3387-7_36 · DOI
- 10.1002/cbic.200700070 · DOI
- 10.1371/journal.pone.0046870 · DOI
- 10.1093/infdis/jiz528 · DOI
- 10.1016/j.vaccine.2009.12.046 · DOI
- Waleed M. H., 2017, Curr. Drug Delivery, 14, 935
- 10.3390/M566 · DOI
- 10.1371/journal.pone.0030146 · DOI
- 10.1021/ol049905y · DOI
- 10.1016/S0952-7915(96)80124-5 · DOI
- 10.2217/nnm.14.187 · DOI
- 10.1086/505146 · DOI
- 10.1016/j.ymthe.2016.11.002 · DOI
- 10.1021/ol3007925 · DOI
- 10.2217/nnm-2016-0291 · DOI
Metadata
- Authors
- Madge, H. Y. R., Sharma, H., Hussein, W. M., Khalil, Z. G., Capon, R. J., Toth, I., & Stephenson, R. J.
- Affiliations
- The University of Queensland (AU)
- School of Chemistry and Molecular Biosciences, The University of Queensland, Brisbane 4072, Australia
- Corresponding author
- Stephenson, Rachel J.
- ORCID
- Venue
- Journal of Medicinal Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2020-04-29
- Volume
- 63
- Issue
- 10
- Pages
- 5387-5397
- ISSN
- 0022-2623 (ISSN-L)
- 1520-4804
- OpenAlex
- W3020711697
- Cited by
- 19
- References
- 38
- Citations by year
- 2026: 1 · 2025: 4 · 2024: 3 · 2023: 3 · 2022: 3 · 2021: 5
- FWCI
- 0.88
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- Locations
- Journal of Medicinal Chemistry (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Health and Medical Research Council (APP1132975)
- Topics
- Physical Sciences › Chemistry › Organic Chemistry › Chemical Synthesis and Analysis
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Biochemical and Structural Characterization
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › vaccines and immunoinformatics approaches
- Keywords
- Streptococcus pyogenes, cyclic lipopeptides, self-adjuvanting vaccine, structure-activity relationship, B-cell epitopes, T-helper epitopes, opsonization, rheumatic heart disease, IgG, cyclic peptides
- MeSH terms
- Animals, Anti-Bacterial Agents, Antigens, Bacterial, Bacterial Vaccines, Female, Humans, Mice, Inbred C57BL, Streptococcal Infections, Streptococcus pyogenes, Structure-Activity Relationship, Chemotherapy, Adjuvant, Mice, Lipopeptides
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
